Cannabidiol, neuroprotection and neuropsychiatric disorders
Abstract
Cannabidiol (CBD) is a non-psychotomimetic phytocannabinoid derived from Cannabis sativa. It has possible therapeutic effects over a broad range of neuropsychiatric disorders. CBD attenuates brain damage associated with neurodegenerative and/or ischemic conditions. It also has positive effects on attenuating psychotic-, anxiety- and depressive-like behaviors. Moreover, CBD affects synaptic plasticity and facilitates neurogenesis. The mechanisms of these effects are still not entirely clear but seem to involve multiple pharmacological targets. In the present review, we summarized the main biochemical and molecular mechanisms that have been associated with the therapeutic effects of CBD, focusing on their relevance to brain function, neuroprotection and neuropsychiatric disorders.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CBD's therapeutic potential for reducing depression-like behavior has been shown.
“CBD’s therapeutic potential for reducing depression-like behavior has been shown, since it interacts with a wide range of brain molecules395,396.”
From Epigenetic regulation in major depression and other stress-related disorders: molecular mechanisms, clinical relevance and therapeutic potential (2023) · cites this paper as [395]
Cites
Safety and side effects of cannabidiol, a Cannabis sativa constituent
Machado Bergamaschi, M., Helena Costa Queiroz, R., Waldo Zuardi, A., & Alexandre S. Crippa, J. (2011) · Current Drug Safety · doi:10.2174/157488611798280924 · Cited by 558 · see citing works
Carrier, E. J., Auchampach, J. A., & Hillard, C. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511232103 · Cited by 497 · see citing works
Campos, A. C., Moreira, F. A., Gomes, F. V., Del Bel, E. A., & Guimarães, F. S. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0389 · Cited by 475 · see citing works
Self-citationEsposito, G., Scuderi, C., Valenza, M., Togna, G. I., Latina, V., De Filippis, D., Cipriano, M., Carratù, M. R., Iuvone, T., & Steardo, L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028668 · Cited by 410 · see citing works
Lastres-Becker, I., Molina-Holgado, F., Ramos, J. A., Mechoulam, R., & Fernández-Ruiz, J. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.11.009 · Cited by 407 · see citing works
Effects of ipsapirone and cannabidiol on human experimental anxiety
Zuardi, A. W., Cosme, R. A., Graeff, F. G., & Guimarães, F. S. (1993) · Journal of Psychopharmacology · doi:10.1177/026988119300700112 · Cited by 364 · see citing works
Rock, E., Bolognini, D., Limebeer, C., Cascio, M., Anavi‐Goffer, S., Fletcher, P., Mechoulam, R., Pertwee, R., & Parker, L. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01621.x · Cited by 255 · see citing works
Anti-inflammatory effects of fluoxetine in lipopolysaccharide(LPS)-stimulated microglial cells
Liu, D., Wang, Z., Liu, S., Wang, F., Zhao, S., & Hao, A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.04.033 · Cited by 221 · see citing works
Scuderi, C., Steardo, L., & Esposito, G. (2014) · Phytotherapy Research · doi:10.1002/ptr.5095 · Cited by 161 · see citing works
Fogaça, M. V., Reis, F. M. C. V., Campos, A. C., & Guimarães, F. S. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.10.012 · Cited by 153 · see citing works
Self-citationDecreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol
Gomes, F. V., Llorente, R., Del Bel, E. A., Viveros, M.-P., López-Gallardo, M., & Guimarães, F. S. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.01.015 · Cited by 147 · see citing works
Mecha, M., Torrao, A. S., Mestre, L., Carrillo-Salinas, F. J., Mechoulam, R., & Guaza, C. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.71 · Cited by 140 · see citing works
Janefjord, E., Mååg, J. L. V., Harvey, B. S., & Smid, S. D. (2014) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-013-9984-x · Cited by 118 · see citing works
Harvey, B. S., Ohlsson, K. S., Mååg, J. L. V., Musgrave, I. F., & Smid, S. D. (2012) · NeuroToxicology · doi:10.1016/j.neuro.2011.12.015 · Cited by 82 · see citing works
Valvassori, S. S., Elias, G., de Souza, B., Petronilho, F., Dal-Pizzol, F., Kapczinski, F., Trzesniak, C., Tumas, V., Dursun, S., Nisihara Chagas, M. H., et al. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881109106925 · Cited by 80 · see citing works
Barichello, T., Ceretta, R. A., Generoso, J. S., Moreira, A. P., Simões, L. R., Comim, C. M., Quevedo, J., Vilela, M. C., Zuardi, A. W., Crippa, J. A., et al. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.09.053 · Cited by 76 · see citing works
Campos, A. C., de Paula Soares, V., Carvalho, M. C., Ferreira, F. R., Vicente, M. A., Brandão, M. L., Zuardi, A. W., Zangrossi, H., & Guimarães, F. S. (2013) · Psychopharmacology · doi:10.1007/s00213-012-2878-7 · Cited by 65 · see citing works
Hosseinzadeh, M., Nikseresht, S., Khodagholi, F., Naderi, N., & Maghsoudi, N. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-015-0703-6 · Cited by 61 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Yuan, M., Yang, B., Rothschild, G., Mann, J. J., Sanford, L. D., Tang, X., Huang, C., Wang, C., & Zhang, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01519-z · Cited by 246 · see citing works
“394 CBD ’ s therapeutic potential for reducing depression-like behavior has been shown, since it interacts with a wide range of brain molecules 395,396 .”
BackgroundVallée, A., Lecarpentier, Y., Guillevin, R., & Vallée, J.-N. (2017) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmx073 · Cited by 226 · see citing works
Campos, A. C., Fogaça, M. V., Scarante, F. F., Joca, S. R. L., Sales, A. J., Gomes, F. V., Sonego, A. B., Rodrigues, N. S., Galve-Roperh, I., & Guimarães, F. S. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00269 · Cited by 175 · see citing works
Self-citationde Faria, S. M., de Morais Fabrício, D., Tumas, V., Castro, P. C., Ponti, M. A., Hallak, J. E., Zuardi, A. W., Crippa, J. A. S., & Chagas, M. H. N. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119895536 · Cited by 140 · see citing works
Clinical Staging for Youth Mental Disorders: Progress in Reforming Diagnosis and Clinical Care
McGorry, P. D., & Mei, C. (2021) · Annual Review of Developmental Psychology · doi:10.1146/annurev-devpsych-050620-030405 · Cited by 38 · see citing works
- Authors
- Campos, A. C., Fogaça, M. V., Sonego, A. B., & Guimarães, F. S.
- Affiliations
- Universidade de São Paulo (BR)
- Corresponding author
- Campos, Alline C.
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 112
- Pages
- 119-127
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W2283995152
- Cited by
- 446
- References
- 18
- Citations by year
- 2026: 32 · 2025: 30 · 2024: 44 · 2023: 85 · 2022: 43 · 2021: 74 · 2020: 43 · 2019: 36 · 2018: 29 · 2017: 23 · 2016: 7
- FWCI
- 3.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacological Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
- Keywords
- cannabidiol, neuroprotection, neuropsychiatric disorders, neurodegeneration, cerebral ischemia, psychosis, anxiety, depression, synaptic plasticity, neurogenesis, phytocannabinoids, Cannabis sativa, molecular mechanisms
- MeSH terms
- Neuroprotection, Animals, Mental Disorders, Brain Diseases, Cannabidiol, Clinical Trials as Topic, Humans, Neuroprotective Agents, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review